Related Experiment Video
Updated: Aug 19, 2025

Author Spotlight: Advancements in Retroperitoneal Approach for Necrotizing Pancreatitis
Published on: March 15, 2024
[Pancreatic pseudocyst after pegaspargase treatment in six children]
J B Sun1, Y H Huang2, H Chang2
1Department of Pediatrics, Peking University Third Hospital, Beijing 100191, China.
Insights
Pediatric pancreatic pseudocyst following pegaspargase chemotherapy can be asymptomatic. Early diagnosis via imaging is crucial. Conservative management is preferred initially, with endoscopic drainage for enlarging cysts.
Area of Science:
- Pediatric Gastroenterology
- Oncology
- Medical Imaging
Context:
- Pegaspargase is a chemotherapy agent used in pediatric oncology.
- Pancreatic pseudocysts are a potential complication of certain medical treatments.
- This study focuses on a specific cohort of children treated at Peking University Third Hospital.
Purpose:
- To investigate the clinical features and management strategies for pancreatic pseudocysts that develop after pegaspargase treatment in children.
- To analyze the timeline from pegaspargase administration to pseudocyst diagnosis.
- To evaluate the effectiveness and safety of different treatment modalities.
Summary:
- Six pediatric cases of pancreatic pseudocyst post-pegaspargase were analyzed.
- Abdominal pain was the primary symptom of pancreatitis.
- Initially asymptomatic pseudocysts often enlarged under conservative care, necessitating endoscopic ultrasound-guided or ERCP-guided drainage.
- Successful cyst resolution was achieved with endoscopic interventions, though one case required surgery.
Impact:
- Highlights the importance of vigilant monitoring for pancreatic pseudocysts in children receiving pegaspargase.
- Provides insights into the natural history and optimal treatment pathways for this complication.
- Emphasizes the role of endoscopic procedures in managing pediatric pancreatic pseudocysts effectively.
Abstract:
Objective: To investigate the clinical characteristics and treatment of pancreatic pseudocyst after pegaspargase treatment in children. Methods: The clinical data of 6 children with pancreatic pseudocyst after pegaspargase treatment in the Department of Pediatrics in Peking University Third Hospital from July 2018 to February 2021 were analyzed retrospectively. Results: There were 4 males and 2 females, and their age of onset was 9.5 (5.8, 13.0) years. The total number of pegaspargase applications was 2.5 (2.0, 3.5) times. The course from the last dose of pegaspargase to the onset of pancreatitis was 11.0 (9.0, 17.2) days, and 42.5 (35.0, 129.5) days from the onset of pancreatitis to the diagnosis of pancreatic pseudocyst. Abdominal pain was the most prominent manifestation of pancreatitis (6/6). All of the 6 children were asymptomatic when pancreatic pseudocyst was noted, and were treated conservatively at first, but one case later developed intermittent abdominal distension or nausea after eating. All the cases had pancreatic pseudocyst enlargement during the conservative treatment. Three children were treated with endoscopic ultrasound-guided transgastric drainage, and the cyst disappeared from 10 days to 4 months after the operation. The other 3 children received endoscopic retrograde cholangiopancreatography (ERCP)-guided transpapillary drainage, but one of them turned to surgery due to pancreatic duct stricture, and in the rest 2 children the cyst disappeared at 1 and 3 months after operation respectively. Regarding safety issues, 1 child who received ERCP-guided transpapillary drainage had acute postoperative pancreatitis, which were improved after treatment, and the other 5 had no complications. Conclusions: Pancreatic pseudocyst after pegaspargase chemotherapy can be asymptomatic in the early stage, and should be diagnosed with a history of pegaspargase treatment and timely imaging examination. Conservative treatment is the first choice for asymptomatic pseudocyst. When the pseudocyst enlarges, different endoscopic drainage treatments are required according to whether the pseudocyst is connected with the main pancreatic duct.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Acute Pancreatitis II: Clinical Manifestations and Management

